摘要
【目的】观察瑞格列奈与罗格列酮联合治疗2型糖尿病对早期胰岛素分泌相的影响。【方法】70例初诊2型糖尿病患者,分为单纯口服瑞格列奈33例(治疗组),瑞格列奈和罗格列酮联合治疗37例(强化组)。比较治疗前后两组患者空腹血糖、餐后2h时血糖、糖化血红蛋白、餐后1h、2h血浆胰岛素的变化。【结果】治疗组餐后2h血糖较治疗前明显下降(P<0.05),餐后1h血浆胰岛素明显升高(P<0.05);强化组治疗后空腹血糖,餐后2h血糖较治疗前明显下降(P<0.05),餐后1h血浆胰岛素显著升高(P<0.01),餐后2h血浆胰岛素降低,且餐后2h血浆胰岛素显著低于餐后1h血浆胰岛素(P<0.05)。【结论】瑞格列奈可改善胰岛素早期分泌时相,但恢复时相峰值困难,瑞格列奈与罗格列奈联合治疗可使2型糖尿病胰岛素早期分泌相恢复,餐后血糖控制更好。
[Objective]To observe the effect of the firstphase insulin secretion in therapeutic alliance of Repaglinide and Rosiglitazone type 2 diabetes. [Methods]Seventy patients with preliminary diagnosis type 2 diabetes were enrolled in this study, in which 33 patients received Repaglinide （trial）and 37 patients received Repaglinide and Rosiglitazone（augmentation）,The changes of the fasting blood glucose （FBG）, 2-hour postprandial blood glucose （PBG）, HbAlc levels, 1-hour plasmic insulin, 2-hour plasmic insulin were compared with the baseline. [Results]Repaglinide visibly reduced PBG（ P 〈0.05）, It significantly increased 1-hour plasmic insulin（ P 〈0.05）. Repaglinide and Rosiglitazone visibly reduced FBG and PBG（ P 〈0. 05, P〈0.01 ）, they significantly increased 1-hour plasmic insulin（ P〈0.01）and reduced 2-hour plasmic insulin, 2-hour plasmic insulin were significantly lower than 1-hour plasmic insulin（ P〈0. 05）. [Conclusion]Repaglinide may improve the early insulin release,but full recovery of the phase peak amplitude is difficult , the therapeutic alliance of Repaglinide and Rosiglitazone may recover the early insulin release and PBG may be better controled.
出处
《医学临床研究》
CAS
2006年第3期300-301,304,共3页
Journal of Clinical Research
